West Pharmaceutical Services (NYSE:WST) announced stronger-than-expected earnings and revenue for the fourth quarter of 2025, alongside issuing its financial guidance for fiscal year 2026. The company reported an EPS of $2.04, surpassing the anticipated $1.83, while revenue reached $805 million against an expected $795.7 million. For FY 2026, WST projects its EPS to be between $7.85 and $8.20 per share. The company also issued revenue guidance for FY 2026, expecting figures to range from $3.2 billion to $3.3 billion. Analysts maintain a 'Buy' rating for WST, with a consensus price target of $326.22, reflecting confidence in the company's future performance. Strong institutional ownership, standing at approximately 93.9%, further underscores this robust support.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis